IQV
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- Forward P/E of 11.29 is very low for the sector
- PEG ratio < 1.0 indicates undervaluation
- Current price is significantly above the defensive Graham Number
Ref Growth rates
- Double-digit revenue growth (10.3%)
- Strong earnings acceleration (23.6% YoY)
- Risks associated with contract underpricing and productivity objectives
Ref Historical trends
- Long-term track record of beating earnings estimates over 25 quarters
- Poor 5-year price performance (-32.5%)
- Sharp recent 6-month decline
Ref Altman Z-Score, Piotroski F-Score
- Strong Piotroski F-Score (7/9)
- High ROE (21.44%)
- Debt/Equity of 2.46 is high
- Current ratio (0.75) indicates potential liquidity pressure
Ref Yield, Payout
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IQV and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IQV
IQVIA Holdings Inc.
Primary
|
-32.5% | -15.5% | +5.9% | -27.1% | -4.3% | -9.5% |
|
BIIB
Biogen Inc.
Peer
|
-34.2% | -34.1% | +34.0% | +30.9% | -2.5% | -0.3% |
|
HUM
Humana Inc.
Peer
|
-46.1% | -55.1% | -11.3% | -21.4% | +38.4% | +5.7% |
|
NTRA
Natera, Inc.
Peer
|
+93.7% | +306.2% | +36.5% | +15.5% | +4.8% | -1.7% |
|
RPRX
Royalty Pharma plc
Peer
|
+34.5% | +51.1% | +57.0% | +36.6% | +9.2% | +4.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IQV
IQVIA Holdings Inc.
|
BULLISH | $26.69B | 20.25 | 21.4% | 8.3% | $158.98 | |
|
BIIB
Biogen Inc.
|
NEUTRAL | $26.91B | 20.83 | 7.4% | 13.1% | $183.33 | Compare |
|
HUM
Humana Inc.
|
BEARISH | $27.58B | 23.37 | 7.0% | 0.9% | $229.72 | Compare |
|
NTRA
Natera, Inc.
|
NEUTRAL | $29.37B | - | -14.3% | -9.0% | $207.19 | Compare |
|
RPRX
Royalty Pharma plc
|
BEARISH | $29.64B | 28.09 | 13.2% | 32.4% | $50.0 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-06 | BOUSBIB ARI B | Chief Executive Officer | Stock Award | 57,177 | - |
| 2026-02-06 | BRUEHLMAN RONALD E | Chief Financial Officer | Stock Award | 16,335 | - |
| 2026-02-06 | SHERBET ERIC M | General Counsel | Stock Award | 6,806 | - |
| 2026-02-06 | STAUB WALTER. RICHARD III | Officer | Stock Award | 2,722 | - |
| 2026-02-06 | CHEROFSKY KERIANN | Officer | Stock Award | 1,087 | - |
| 2026-02-06 | PATEL BHAVIK | Officer | Stock Award | 4,083 | - |
| 2026-02-06 | GRENFELL ALISTAIR | Officer | Stock Award | 11,795 | - |
| 2025-12-18 | BOUSBIB ARI B | Chief Executive Officer | Sale | 36,564 | $8,132,931 |
| 2025-12-18 | BOUSBIB ARI B | Chief Executive Officer | Option Exercise | 50,000 | $2,995,000 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
IQVIA is a global provider of clinical research services and healthcare intelligence leveraging AI and advanced analytics across more than 100 countries. Key financial risks include the potential loss or delay of contracts, contract underpricing, and cost overruns. Additionally, the company's results may be adversely affected by failures to meet internal productivity objectives or successfully execute growth initiatives in new markets.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning IQV from our newsroom.